Bioequivalence assessment of the two brands of glimepiride tablets
Background/Aim. Glimepiride, as an antidiabetic from the group of sulfonylurea, is administered perorally in the treatment of diabetes mellitus. The aim of this study was to compare pharmacokinetic profiles and relative bioavailabilities of the two oral formulations of glimepiride, generic and innov...
Main Authors: | Jovanović Dušan, Stojšić Dragan, Zlatković Milica, Jović-Stošić Jasmina, Jovanović Miodrag |
---|---|
Format: | Article |
Language: | English |
Published: |
Military Health Department, Ministry of Defance, Serbia
2006-01-01
|
Series: | Vojnosanitetski Pregled |
Subjects: | |
Online Access: | http://www.doiserbia.nb.rs/img/doi/0042-8450/2006/0042-84500612015J.pdf |
Similar Items
-
Type 2 diabetes therapy at the time of diagnosis. Glimepiride: property, efficiency, safety
by: Olga Mikhailovna Smirnova
Published: (2009-03-01) -
ECONOMIC REASONS FOR GENERIC CHOICE
by: N. P. Kutishenko, et al.
Published: (2016-01-01) -
WHAT IS THERAPEUTIC EQUIVALENCE OF GENERIC DRUG AND HOW TO PROVE IT
by: N. P. Kutishenko, et al.
Published: (2016-01-01) -
Generic drugs: benefit/risk ratio
by: E. A. Ushkalova, et al.
Published: (2021-12-01) -
Increased Frequency of Severe Hypoglycemia with the Modified-Release Gliclazide Compared to Glimepiride in Diabetic Older Adults; Propensity Score-Adjusted Analysis
by: Fouad Algendy A, et al.
Published: (2022-05-01)